Company intelligence / Profile preview
PharmaEssentia
Taichung, Taichung, Taiwanhq.pharmaessentia.com ↗
- Ownership
- Public · 6446
- Development stage
- Other
01
Overview
PharmaEssentia has successfully developed Ropeginterferon alfa‐2b, marketed as BESREMI®, which has received approval for the treatment of polycythemia vera in both Europe and the United States. The company continues to expand its pipeline targeting hematologic diseases such as MPNs, with ongoing R&D into additional biologics and small molecule therapies. It operates a cGMP biologics facility certified by TFDA and compliant with FDA/EMA standards.
- Therapeutic areas
- OtherOncologyInfectious Diseases
- Modalities
- Biologics (notably pegylated interferons)Small molecules and antibodies (in pipeline development)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
AOP Orphan Pharmaceuticals AG—co-development of BESREMI® for European market.
04
Financials
- Market cap
- $16B
- Total revenue
- $477.2M
- Enterprise value
- $15.3B
Beyond the preview
Go deeper on PharmaEssentia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaEssentia.